Industry News Archive

[Registration Open] Enhertu National Broadcast

March 4 | 6:30 PM EST and 8:30 PM EST

Join our expert panel to discuss the incidence of disease and unmet needs of patients with HER2+ advanced gastric or gastroesophageal cancer; explore the efficacy and safety results of Enhertu® in DESTINY-Gastric01 who have received a prior trastuzumab-based regimen; Identify key safety considerations for Enhertu®, and explain the dosage and administration of Enhertu®

A live Q&A session will follow. For more information click here.


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us